Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma

Simple Summary Chondrosarcomas develop chemoresistance to standard anticancer drugs, making it difficult to control unresectable or metastatic chondrosarcomas. To improve the clinical outcomes of chondrosarcoma, new treatment approaches, such as molecule-targeting agents and immunotherapy, are needed. Recent research has revealed promising biomarkers and therapeutic targets for chondrosarcoma. In addition, several molecule-targeting agents have shown favorable antitumor activities in several clinical studies in patients with advanced sarcomas, including chondrosarcoma. This review summarizes recent basic studies on biomarkers and therapeutic targets and recent clinical studies on treating chondrosarcomas. Due to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including IDH1/2 and COL2A1. Several molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies in patients with advanced chondrosarcomas. This review summarizes recent basic studies on biomarkers and molecular targets and recent clinical studies on the treatment of chondrosarcomas.

Automated summary

Chondrosarcomas develop resistance to standard anticancer drugs, making it challenging to control the disease. New treatment approaches, such as molecule-targeting agents and immunotherapy, are needed. Recent studies have identified promising biomarkers and therapeutic targets for chondrosarcoma, and various molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies. This review summarizes recent research on biomarkers and therapeutic targets, as well as clinical studies on the treatment of chondrosarcomas.